Market Overview

Targeted Medical Pharma Presents at the California Association of Health Facilities' Annual Convention

LOS ANGELES--(BUSINESS WIRE)--

David Silver, M.D., executive vice president of scientific and medical affairs at Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), discussed the utilization of prescription only medical foods in a skilled nursing setting at this year's California Association of Health Facilities' 62nd annual convention, held in Palm Springs, Calif., on November 12.

The presentation, “Safer and More Effective Pharmacologic Alternatives,” focused on the safety and efficacy of prescription medical foods for the long term management of pain, cognitive and sleep disorders. Dr. Silver also presented initial data outcomes from an ongoing clinical trial among nursing home patients administered with the medical foods Sentra AM® and Sentra PM®. Preliminary results among trial participants show an improvement in alertness, memory recall, balance, quality of sleep, sleep latency, sleep duration, as well as a reduction in nighttime awakenings.

“Medical foods provide physicians with a non-addictive and effective prescription alternative to the traditional pharmacologic treatments currently utilized in the skilled nursing setting,” said board certified rheumatologist Dr. Silver. “These medications offer patients a safer way to manage pain, sleep and cognitive disorders, without the risks associated with many single molecule agents currently utilized in this setting.”

Dr. Silver's presentation can be downloaded by clicking here or visiting http://www.slideshare.net/TDMEDPHARMA.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, and pharmacies for the treatment of chronic disease including pain syndromes, obesity, sleep and cognitive disorders. The company manufactures nine proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Based in Los Angeles, the company's proprietary pharmaceutical therapeutic systems are currently sold in the United States and Japan. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release regarding Dr. David Silver's presentation, “Safer and More Effective Pharmacologic Alternatives,” and initial data results from an ongoing clinical trial among nursing home patients administered with the medical foods Sentra AM® and Sentra PM®, may contain forward-looking statements related to Targeted Medical Pharma's business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Media Contacts:
PondelWilkinson
George Medici | gmedici@pondel.com
Ron Neal | rneal@pondel.com
(310) 279-5980
or
Investor Contacts:
PondelWilkinson
Roger Pondel | Matt Sheldon
investors@tmedpharma.com
(310) 279-5975

 

Around the Web, We're Loving...

Get Benzinga's Newsletters